QQQ   430.00 (-0.25%)
AAPL   172.54 (-0.09%)
MSFT   413.88 (+0.06%)
META   497.97 (-0.45%)
GOOGL   154.01 (-0.55%)
AMZN   182.71 (-0.50%)
TSLA   154.95 (-4.04%)
NVDA   862.12 (+0.25%)
AMD   162.51 (+1.37%)
NIO   3.72 (-4.37%)
BABA   69.60 (-1.44%)
T   16.07 (-1.05%)
F   12.04 (-1.55%)
MU   118.76 (-2.15%)
GE   153.79 (+0.06%)
CGC   6.82 (-2.29%)
DIS   112.80 (-0.13%)
AMC   2.51 (+1.62%)
PFE   25.84 (-0.27%)
PYPL   62.96 (-0.87%)
XOM   119.51 (-0.14%)
QQQ   430.00 (-0.25%)
AAPL   172.54 (-0.09%)
MSFT   413.88 (+0.06%)
META   497.97 (-0.45%)
GOOGL   154.01 (-0.55%)
AMZN   182.71 (-0.50%)
TSLA   154.95 (-4.04%)
NVDA   862.12 (+0.25%)
AMD   162.51 (+1.37%)
NIO   3.72 (-4.37%)
BABA   69.60 (-1.44%)
T   16.07 (-1.05%)
F   12.04 (-1.55%)
MU   118.76 (-2.15%)
GE   153.79 (+0.06%)
CGC   6.82 (-2.29%)
DIS   112.80 (-0.13%)
AMC   2.51 (+1.62%)
PFE   25.84 (-0.27%)
PYPL   62.96 (-0.87%)
XOM   119.51 (-0.14%)
QQQ   430.00 (-0.25%)
AAPL   172.54 (-0.09%)
MSFT   413.88 (+0.06%)
META   497.97 (-0.45%)
GOOGL   154.01 (-0.55%)
AMZN   182.71 (-0.50%)
TSLA   154.95 (-4.04%)
NVDA   862.12 (+0.25%)
AMD   162.51 (+1.37%)
NIO   3.72 (-4.37%)
BABA   69.60 (-1.44%)
T   16.07 (-1.05%)
F   12.04 (-1.55%)
MU   118.76 (-2.15%)
GE   153.79 (+0.06%)
CGC   6.82 (-2.29%)
DIS   112.80 (-0.13%)
AMC   2.51 (+1.62%)
PFE   25.84 (-0.27%)
PYPL   62.96 (-0.87%)
XOM   119.51 (-0.14%)
QQQ   430.00 (-0.25%)
AAPL   172.54 (-0.09%)
MSFT   413.88 (+0.06%)
META   497.97 (-0.45%)
GOOGL   154.01 (-0.55%)
AMZN   182.71 (-0.50%)
TSLA   154.95 (-4.04%)
NVDA   862.12 (+0.25%)
AMD   162.51 (+1.37%)
NIO   3.72 (-4.37%)
BABA   69.60 (-1.44%)
T   16.07 (-1.05%)
F   12.04 (-1.55%)
MU   118.76 (-2.15%)
GE   153.79 (+0.06%)
CGC   6.82 (-2.29%)
DIS   112.80 (-0.13%)
AMC   2.51 (+1.62%)
PFE   25.84 (-0.27%)
PYPL   62.96 (-0.87%)
XOM   119.51 (-0.14%)

Achilles Therapeutics (ACHL) SEC Filings & 10K Form

$0.85
+0.03 (+3.21%)
(As of 09:45 AM ET)

Recent Achilles Therapeutics SEC Filings

DateFilerForm TypeView
04/04/2024
7:12 AM
Achilles Therapeutics (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
04/04/2024
7:25 AM
Achilles Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/29/2024
3:30 PM
Achilles Therapeutics (Subject)
Artal International S.C.A. (Filed by)
Form SC 13G/A
02/13/2024
5:40 PM
Achilles Therapeutics (Subject)
Syncona Portfolio Ltd (Filed by)
Form SC 13G/A
02/01/2024
12:14 PM
Achilles Therapeutics (Subject)
Peggs Karl Stuart Dr (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/13/2023
3:36 PM
Achilles Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/01/2023
4:26 PM
Achilles Therapeutics (Subject)
Peggs Karl Stuart Dr (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/22/2023
3:42 PM
Achilles Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/17/2023
2:16 PM
Achilles Therapeutics (Subject)
Peggs Karl Stuart Dr (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/04/2023
6:42 AM
Achilles Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/10/2023
7:46 AM
Achilles Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/24/2023
4:02 PM
Achilles Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:ACHL) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners